DiscoverOncology Brothers: Practice-Changing Cancer DiscussionsManaging Toxicities of CDK4/6 Inhibitors in Hormone Positive Breast Cancer - Dr. Stephanie Graff
Managing Toxicities of CDK4/6 Inhibitors in Hormone Positive Breast Cancer - Dr. Stephanie Graff

Managing Toxicities of CDK4/6 Inhibitors in Hormone Positive Breast Cancer - Dr. Stephanie Graff

Update: 2025-10-16
Share

Description

In this episode of Oncology Brothers, we dived deep into the world of CDK4-6 inhibitors, focusing on their side effects and management in breast cancer treatment. Joined by an esteemed guest, Dr. Stephanie Graff, a medical breast oncologist from Brown University Health. We explored the side effects and management strategies for three commonly used CDK4/6 inhibitors: ribociclib, abemaciclib, and palbociclib.


Key topics discussed include:

•⁠ ⁠The evolving role of CDK4/6 inhibitors in early breast cancer and adjuvant settings.

•⁠ ⁠Detailed management of side effects such as QT prolongation, liver function tests, and diarrhea.

•⁠ ⁠The importance of shared decision-making with patients regarding treatment options.

•⁠ ⁠Insights into the latest clinical trial data and its implications for practice.


Whether you're a healthcare professional or someone interested in oncology, this episode provides valuable insights into optimizing patient care while managing the complexities of CDK4-6 inhibitors.


Follow us on social media:

•⁠ ⁠X/Twitter: https://twitter.com/oncbrothers

•⁠ ⁠Instagram: https://www.instagram.com/oncbrothers

•⁠ Website: https://oncbrothers.com/


Don't forget to like, subscribe, and check out our other episodes for more discussions on oncology treatments and patient management strategies!


#CDK4/6inhibitors #BreastCancer #Ribociclib #Abemaciclib #Palbociclib #OncologyBrothers #SideEffectManagement #HRpositiveBC

Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Managing Toxicities of CDK4/6 Inhibitors in Hormone Positive Breast Cancer - Dr. Stephanie Graff

Managing Toxicities of CDK4/6 Inhibitors in Hormone Positive Breast Cancer - Dr. Stephanie Graff

Oncology Brothers